We have been evaluating pacritinib for a variety of indications in clinical trials.
Trial/status Indication Overview
Phase 3 Ongoing

Myelofibrosis with severe thrombocytopenia

The PACIFICA trial is a randomized, controlled phase 3 study of pacritinib versus Physician’s Choice in patients with primary myelofibrosis, post polycythemia vera myelofibrosis or post‑essential thrombocythemia myelofibrosis with severe thrombocytopenia (platelet count below 50,000/μL).

Learn more (NCT03165734).

Phase 1/2 Ongoing

Acute Graft Versus Host Disease

This is an investigator-sponsored, single-arm, phase I/II, study of Pacritinib with Sirolimus and Tacrolimus (PAC/SIR/TAC) for the prevention of acute graft versus host disease (GvHD) after matched related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). The study is being conducted at the Mayo Clinic and Moffit Cancer Center.

Learn more (NCT02891603).

Phase 2 Complete

Severe COVID-19

The PRE-VENT study was a randomized, double-blind, placebo-controlled multicenter Phase 2 study, comparing pacritinib plus standard of care versus placebo and standard of care in hospitalized patients with severe COVID-19, including patients with and without cancer, to evaluate whether pacritinib can prevent progression to acute respiratory distress syndrome and mechanical ventilation.

Learn more (NCT04404361).

Phase 3 Complete


PERSIST-1 was a randomized (2:1), open-label, multi-center Phase 3 trial evaluating the efficacy and safety of pacritinib compared to Best Availability Therapy, excluding JAK inhibitors, in 327 patients with myelofibrosis, without exclusion for low platelet counts.

Learn more (NCT01773187).

Phase 3 Complete


PERSIST-2 was a randomized (2:1), open-label, multi-center registration-directed Phase 3 trial evaluating pacritinib compared to Best Available Therapy, including the approved JAK inhibitor dosed according to product label, for patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (≤100,000/μL).

Learn more (NCT02055781).

Phase 2 Complete

TRIAL OVERVIEW: PAC203 was a Phase 2 dose-finding study of pacritinib in patients with myelofibrosis who have received prior ruxolitinib.

Learn more (NCT03165734).

General Clinical Trial Information

Learning More About Clinical Trials

Every modern prescription medicine we have today was studied in hundreds and often thousands of people. Being part of a clinical study can make a difference in the lives of other people.

Finding a Clinical Trial That’s Right For You

If you are considering joining a clinical, you’ll be connected with the team of medical professionals running the trial. They’re looking for participants who are a good fit for their specific study. So before you join, you’ll go through a screening and consent process. This is how the study doctor ensures they enroll the participants that the study drug is being developed to treat. It’s also an opportunity for you to ask them questions and make sure you feel the study is the right fit for you.

Who Can Participate In a Clinical Trial?

Taking part in a research study is different from regular medical care. When in a study, you will primarily interact with the study team. The study team includes the study doctor, nurses, and others who work with the study doctor.

  • You may have additional scheduled visits and procedures, extra laboratory tests and/or follow a modified treatment plan.
  • You can stop participating at any time—the decision to stop will not affect your regular medical care or any benefits to which you are entitled.
  • Where permissible, reimbursement for study-related expenses—such as parking and travel—may be provided.
  • To research a study drug for efficacy and safety, some participants are given the study drug and others are given standard of care or a placebo. Before you consent to join, you will be told how the study works.

For another excellent resource for learning more about clinical trials, visit the National Cancer Institute at the National Institutes of Health.